+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

NovoSeven RT 2017 U.S. Promotional Audit Report

  • ID: 4615908
  • Report
  • Region: United States
  • 28 pages
  • MD Details
1 of 2
The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by NovoSeven RT through reportable promotional activity in 2017 and how does this compare to its peer set in the Glanzmann's Thrombasthenia and Hemophilia markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does Novo Nordisk's depth of coverage vary within key specialties (e.g., Pediatric Medicine, Hematology/Oncology, Medical Oncology, Internal Medicine, Emergency Medicine, and Pathology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for NovoSeven RT throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for NovoSeven RT in 2017?
Data Sources and Methodology:
  • The author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than four years of longitudinal data is available - covering payments to more than 975,000 U.S. healthcare professionals.
  • Over 300 paid interactions across 200 physicians made on behalf of NovoSeven RT were carefully examined to support our analysis.
Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4615908
Adroll
adroll